Add like
Add dislike
Add to saved papers

Uremia: A historical reappraisal of what happened
.

Urea was identified as a urinary salt in 1662 and was the first organic bodily product to be synthesized <italic>in vitro</italic> in 1828. This heralded the end of an era that defined disease as an imbalance between vital life forces, and catalyzed the merging of organic chemical sciences into clinical medicine. The term <italic>urée</italic> (urea) was introduced in 1803, its accumulation in blood was dubbed <italic>urémie</italic> (uremia) in 1847, and the procedure for its removal from urine across semi-permeable membranes designated dialysis in 1861. The advent of modern dialysis in the 20th century provided lifesaving replacement therapy for the universally fatal disease that progressive uremia had been theretofore. Today, the clearance of urea is no longer used as a marker to identify patients with kidney disease; rather it has been adopted as a measure of the adequacy of dialysis, and the "urea toxicity" of yesteryears has been replaced by that of dialyzable "uremic toxins". As a result, the use of the term uremia has become non-uniform and is now applied to variable scenarios ranging from "azotemia" to "kidney failure" and to the symptoms persisting in patients receiving maintenance hemodialysis. In the process, the quest for variably dialyzed uremic toxins has overshadowed the consideration that dialysis is an invasive non-physiologic process that operates counter to normal homeostasis and itself may be toxic.
.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app